2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Warm Autoimmune Hemolytic Anemia: new trials by email Literature Review of Warm Autoimmune Hemolytic Anemia trials Research Report on Warm Autoimmune Hemolytic Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly - Warm Autoimmune Hemolytic Anemia | Phase 2 | Terminated | Immunovant Sciences GmbH | 5 | 2020-08-11 | 2022-07-28 |
| A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) ALXN1830 - Warm Autoimmune Hemolytic Anemia | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2018-01-10 | 2020-05-13 |
orilanolimab (1)
Alexion Pharmaceuticals, Inc. (1) · Immunovant Sciences GmbH (1)
United States (2) · Israel (1) · Jordan (1) · South Korea (1) · Spain (1) · Thailand (1) · United Kingdom (1)